GeneDx Faces Securities Class Action After Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and indicating a sharp deterioration in the company's financial health.
- Class Action Lawsuit: Hagens Berman is investigating whether GeneDx violated federal securities laws, seeking to represent investors who purchased shares between April 16, 2025, and May 4, 2026, highlighting investor dissatisfaction with the company's disclosures.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with Fabric Genomics contributing to a $2.5 million revenue miss and resulting in $31.2 million in impairment charges, showcasing acquisition failures and management missteps.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior expectations, reflecting major shifts in product mix and negative implications for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 56.330
Low
155.00
Averages
171.43
High
200.00
Current: 56.330
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and indicating a sharp deterioration in the company's financial health.
- Class Action Lawsuit: Hagens Berman is investigating whether GeneDx violated federal securities laws, seeking to represent investors who purchased shares between April 16, 2025, and May 4, 2026, highlighting investor dissatisfaction with the company's disclosures.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with Fabric Genomics contributing to a $2.5 million revenue miss and resulting in $31.2 million in impairment charges, showcasing acquisition failures and management missteps.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior expectations, reflecting major shifts in product mix and negative implications for future growth.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Stock Losses
- Class Action Filed: On June 4, 2026, Barrack Rodos & Bacine initiated a class action lawsuit representing purchasers of GeneDx stock from April 16, 2025, to May 4, 2026, alleging violations of the Securities Exchange Act by the company and its executives, which could lead to significant investor losses.
- Financial Loss Disclosure: GeneDx's Q1 2026 report revealed an operational loss of $57.5 million and an EPS of -$0.28, with a drop in adjusted gross margin from 74% to 69%, alongside a $31.3 million impairment loss related to the acquisition of Fabric Genomics, highlighting the acquisition's substantial risks.
- Stock Price Plummet: Following the financial report, GeneDx's stock price fell over 49%, or $33.42 per share, indicating strong market concerns regarding the company's future profitability, which may impact its financing and operational capabilities.
- Investor Actions: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased GeneDx stock during the class period can seek to become the lead plaintiff, reflecting investor concerns over corporate governance and transparency, potentially prompting the company to enhance its disclosure and compliance practices.
See More
GeneDX Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised GeneDX investors of a class action for those who purchased securities between April 16, 2025, and May 4, 2026, with a deadline of August 3, 2026, for filing a lead plaintiff motion, indicating significant legal risks for the company.
- Financial Performance Decline: GeneDX's Q1 2026 financial results missed expectations for both its exome and genome lines, leading to a downward revision of its 2026 revenue guidance from $540-555 million to $475-490 million, reflecting a substantial deterioration in profitability.
- Stock Price Plunge: Following the earnings report, GeneDX's share price fell over 49%, or $33.42 per share, closing at $67.93, demonstrating strong market concerns regarding the company's future prospects.
- Acquisition Loss Disclosure: The company disclosed a goodwill impairment charge of $31.3 million related to the Fabric Genomics acquisition, despite having paid $36.5 million just a year prior, highlighting significant misjudgments in acquisition decisions and their adverse financial impacts.
See More
GeneDx Faces Class Action Lawsuit Over Stock Decline
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must apply by August 3, 2026, to be appointed lead plaintiff in the class action lawsuit, highlighting investor concerns regarding corporate governance and transparency.
- Financial Loss Disclosure: GeneDx's Q1 2026 report revealed a drop in adjusted gross margin from 74% to 69%, a reduction in projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss due to Fabric Genomics, indicating significant financial risks associated with the acquisition.
- Stock Price Plunge Impact: Following the May 4, 2026, earnings announcement, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also lead to increased shareholder participation in the lawsuit, exacerbating the legal risks faced by the company.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strong capabilities and influence in securities fraud cases, which could significantly impact GeneDx's legal outlook.
See More
GeneDx Securities Class Action Reminder for Investors
- Deadline for Claims: Investors must file lead plaintiff applications for the GeneDx securities class action by August 3, 2026, concerning shares purchased between April 16, 2025, and May 4, 2026, or risk losing their right to recover losses.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates for both its exome and genome lines, and lowered its full-year revenue guidance to $475-$490 million from $540-$550 million, indicating significant operational challenges.
- Stock Price Plunge: Following the disappointing earnings report, GeneDx's stock price fell by $33.42, or 49.2%, which not only reflects investor concerns about the company's financial health but may also impact investor confidence and future fundraising efforts.
- Impairment Loss Disclosure: The company disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was previously expected to expand its market and create sustainable revenue streams, but the current situation suggests it has failed to meet strategic expectations.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by August 3, 2026, indicating significant legal challenges ahead for the firm.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, highlighting a concerning decline in profitability.
- Acquisition Impact: The company reported a $31.3 million impairment loss directly linked to its acquisition of Fabric Genomics, which has raised further investor concerns regarding the financial implications of this strategic move.
- Stock Price Plunge: Following the earnings announcement, GeneDx's stock price plummeted by $33.42, or 49.20%, closing at $34.51 per share, reflecting a stark market reaction and pessimism about the company's future outlook.
See More
GeneDx Faces Securities Class Action After Stock Plunge
- Stock Price Crash: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and indicating a sharp deterioration in the company's financial health.
- Class Action Lawsuit: Hagens Berman is investigating whether GeneDx violated federal securities laws, seeking to represent investors who purchased shares between April 16, 2025, and May 4, 2026, highlighting investor dissatisfaction with the company's disclosures.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with Fabric Genomics contributing to a $2.5 million revenue miss and resulting in $31.2 million in impairment charges, showcasing acquisition failures and management missteps.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, significantly lower than prior expectations, reflecting major shifts in product mix and negative implications for future growth.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Stock Losses
- Class Action Filed: On June 4, 2026, Barrack Rodos & Bacine initiated a class action lawsuit representing purchasers of GeneDx stock from April 16, 2025, to May 4, 2026, alleging violations of the Securities Exchange Act by the company and its executives, which could lead to significant investor losses.
- Financial Loss Disclosure: GeneDx's Q1 2026 report revealed an operational loss of $57.5 million and an EPS of -$0.28, with a drop in adjusted gross margin from 74% to 69%, alongside a $31.3 million impairment loss related to the acquisition of Fabric Genomics, highlighting the acquisition's substantial risks.
- Stock Price Plummet: Following the financial report, GeneDx's stock price fell over 49%, or $33.42 per share, indicating strong market concerns regarding the company's future profitability, which may impact its financing and operational capabilities.
- Investor Actions: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased GeneDx stock during the class period can seek to become the lead plaintiff, reflecting investor concerns over corporate governance and transparency, potentially prompting the company to enhance its disclosure and compliance practices.
See More
GeneDX Investors Class Action Notice Issued
- Class Action Notice: The Portnoy Law Firm has advised GeneDX investors of a class action for those who purchased securities between April 16, 2025, and May 4, 2026, with a deadline of August 3, 2026, for filing a lead plaintiff motion, indicating significant legal risks for the company.
- Financial Performance Decline: GeneDX's Q1 2026 financial results missed expectations for both its exome and genome lines, leading to a downward revision of its 2026 revenue guidance from $540-555 million to $475-490 million, reflecting a substantial deterioration in profitability.
- Stock Price Plunge: Following the earnings report, GeneDX's share price fell over 49%, or $33.42 per share, closing at $67.93, demonstrating strong market concerns regarding the company's future prospects.
- Acquisition Loss Disclosure: The company disclosed a goodwill impairment charge of $31.3 million related to the Fabric Genomics acquisition, despite having paid $36.5 million just a year prior, highlighting significant misjudgments in acquisition decisions and their adverse financial impacts.
See More
GeneDx Faces Class Action Lawsuit Over Stock Decline
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must apply by August 3, 2026, to be appointed lead plaintiff in the class action lawsuit, highlighting investor concerns regarding corporate governance and transparency.
- Financial Loss Disclosure: GeneDx's Q1 2026 report revealed a drop in adjusted gross margin from 74% to 69%, a reduction in projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss due to Fabric Genomics, indicating significant financial risks associated with the acquisition.
- Stock Price Plunge Impact: Following the May 4, 2026, earnings announcement, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also lead to increased shareholder participation in the lawsuit, exacerbating the legal risks faced by the company.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strong capabilities and influence in securities fraud cases, which could significantly impact GeneDx's legal outlook.
See More
GeneDx Securities Class Action Reminder for Investors
- Deadline for Claims: Investors must file lead plaintiff applications for the GeneDx securities class action by August 3, 2026, concerning shares purchased between April 16, 2025, and May 4, 2026, or risk losing their right to recover losses.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates for both its exome and genome lines, and lowered its full-year revenue guidance to $475-$490 million from $540-$550 million, indicating significant operational challenges.
- Stock Price Plunge: Following the disappointing earnings report, GeneDx's stock price fell by $33.42, or 49.2%, which not only reflects investor concerns about the company's financial health but may also impact investor confidence and future fundraising efforts.
- Impairment Loss Disclosure: The company disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics, which was previously expected to expand its market and create sustainable revenue streams, but the current situation suggests it has failed to meet strategic expectations.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by August 3, 2026, indicating significant legal challenges ahead for the firm.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, highlighting a concerning decline in profitability.
- Acquisition Impact: The company reported a $31.3 million impairment loss directly linked to its acquisition of Fabric Genomics, which has raised further investor concerns regarding the financial implications of this strategic move.
- Stock Price Plunge: Following the earnings announcement, GeneDx's stock price plummeted by $33.42, or 49.20%, closing at $34.51 per share, reflecting a stark market reaction and pessimism about the company's future outlook.
See More
